DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Douillard JY, Ostoros G, Cobo M. , et al.
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Br J Cancer 2014;
110 (01) 55-62
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.